ICPTライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (8 11月 2023 @ 06:00):

Stats
本日の出来高	3.91M
平均出来高	2.05M
時価総額	794.69M
EPS	$0 ( 2024-04-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-17.43
ATR14	$0.410 (2.16%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-08	Akkaraju Srinivas	Sell	640 688	Common Stock
2023-11-08	Akkaraju Srinivas	Sell	8 111	Common Stock
2023-11-08	Akkaraju Srinivas	Sell	12 089	Option to Purchase Common Stock
2023-11-08	Akkaraju Srinivas	Sell	12 790	Option to Purchase Common Stock
2023-11-08	Akkaraju Srinivas	Sell	12 547	Option to Purchase Common Stock

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 1 646 020

ボリューム相関

長: 0.26 (neutral)

短: 0.00 (neutral)

Signal:(75.794) Neutral

Intercept Pharmaceuticals 相関

10 最も正の相関
LIQT	0.919
TREE	0.912
PIRS	0.9
PALT	0.896
HLMN	0.891
IPDN	0.888
VRME	0.888
IDCC	0.885
STX	0.883
LILA	0.883

10 最も負の相関
TUEM	-0.876
AVIR	-0.849
DTSS	-0.843
GMII	-0.842
AHPI	-0.841
CFV	-0.841
JRJC	-0.841
AFYA	-0.832
GOEV	-0.831
APM	-0.824

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Intercept Pharmaceuticals 相関 - 通貨/商品

0.10
( neutral )

0.68
( moderate )

0.57
( weak )

0.36
( neutral )

0.62
( weak )

-0.08
( neutral )

Intercept Pharmaceuticals 財務諸表

Annual	2022
収益:	$285.71M
総利益:	$284.73M (99.66 %)
EPS:	$3.40

FY	2022
収益:	$285.71M
総利益:	$284.73M (99.66 %)
EPS:	$3.40

FY	2021
収益:	$363.47M
総利益:	$360.37M (99.15 %)
EPS:	$-2.88

FY	2020
収益:	$312.69M
総利益:	$307.37M (98.30 %)
EPS:	$-8.34

Financial Reports:

No articles found.

Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.